[CLSTR]
< Back to situations

We’ll email you as it develops, and you can follow the whole thread from day one.

[SITUATION] · [ACTIVE]

2 clusters · 2 sources · 27 days · First seen · Last updated

Categories: HEALTH

Migraine prophylaxis treatment studies

Entities: Topiramate · CGRP monoclonal antibodies · botulinum toxin · Migraine · Atogepant

Overview

In early July 2026, researchers at Bellvitge Hospital reported that the oral CGRP receptor antagonist atogepant significantly reduced migraine attack frequency in patients whose condition was refractory to other therapies.

By early August 2026, a larger prospective study of 90 migraine patients in Germany showed that preventive treatments—including CGRP‑targeted monoclonal antibodies, botulinum toxin, and oral agents such as topiramate and atogepant—were associated with measurable improvements in cognitive performance, particularly executive function, during headache‑free periods. The cognitive gains correlated with reductions in monthly moderate‑to‑severe headache days, confirming the efficacy and tolerability of these prophylactic options.

Timeline

  1. 5 days ago

    [HEALTH] 2 sources
    Migraine Prophylaxis Improves Cognition and Shows Drug Efficacy

    Studies show CGRP antibodies or botulinum toxin improve cognition in migraine patients, while a comparison of topiramate and atogepant confirms both as effective oral preventives.

  2. about 1 month ago

    [HEALTH] 3 sources
    Bellvitge Hospital study finds atogepant cuts migraine attacks in refractory patients

    A Spanish multicenter study of 252 refractory migraine patients found atogepant reduced migraine days by ≥50% in 30% and improved symptoms in 44%, offering a new option for those unresponsive to existingPrevent

Sources

deutschesgesundheitsportal.de · fractal.org.za